

FIG.1

Malignant Breast
96102003G H9C65




FIG.2A

Malignant Breast
9609C033R H9C65




FIG.2B

Normal Breast.
9712C030G H9C65




FIG.2C

MB8 Cell Line
H9C65




FIG.2D

Malignant Breast
96102003G H95C30




FIG.3A

Malignant Breast
9609C033R H95C30




FIG.3B

Normal Breast
9712C030G H95C30



FIG.3C

MB8 Cell Line
H95C30




FIG.3D





FIG.4A



anti-BU101 PAb 10923


FIG.4B

1 2 3 4 3



anti-Mam PAb 10931

FIG.4C



anti-myc MAb

FIG.5A




FIG.5B




FIG.6A






FIG.6B



10918 10923 11543 10931
Polyclonal Antisera, 1:5000

FIG.6C



H85 H68 H111 myc
Monoclonal Antibodies 1:50

FIG.6D

1 2



FIG.7




FIG. 8A




FIG. 8B




FIG.9



FIG.10

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15




FIG.11A

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15






FIG.11B




anti-BU101.3, 10923, 1:5000
sample reduced and boiled

FIG.12A



anti-MAM.1, 10931, 1:5000
sample reduced and boiled

FIG.12B



Polyclonal Antibody 10923
anti-BU101.3


FIG.13A

Reduced Not Reduced
42 43 44 45 46 47 48 42 43 44 45 46 47 48




Polyclonal Antibody 10931
anti-MAM.1

FIG.13B




anti-BU101 polyclonal 10923

FIG. 14A



anti-Mam polyclonal

FIG. 14B



anti-myc, 1:5000

FIG.15

Met Lys Leu Ser Val Cys Leu Leu Leu Val Thr Leu Ala Leu Cys Cys
1 5 10 15
Tyr Gln Ala Asn Ala Glu Phe Cys Pro Ala Leu Val Ser Glu Leu Leu
20 25 30
Asp Phe Phe Phe Ile Ser Glu Pro Leu Phe Lys Leu Ser Leu Ala Lys
35 40 45
Phe Asp Ala Pro Pro Glu Ala Val Ala Ala Lys Leu Gly Val Lys Arg
50 55 60
Cys Thr Asp Gln Met Ser Leu Gln Lys Arg Ser Leu Ile Ala Glu Val
65 70 75 80
Leu Val Lys Ile Leu Lys Lys Cys Ser Val
85 90

FIG.16

ASSEMBLY OF BS106 FROM INDIVIDUAL EXPRESSED TAGS




FIG.17

>BS106 CONSENSUS




CGGCTCGAGCTCTTAGGCTTTGAAGCATTTTTGTCTGTGCTCCCT
GATCTTCAGGTCACCACCATGAAGTTCTTAGCAGTCCTGGTACTC
TTGGGAGTTTCCATCTTTCTGGTCTCTGCCCAGAATCCGACAACA
GCTGCTCCAGCTGACACGTATCCAGCTACTGGTCCTGCTGATGAT
GAAGCCCCTGATGCTGAAACCACTGCTGCTGCAACCACTGCGACC
ACTGCTGCTCCTACCACTGCAACCACCGCTGCTTCTACCACTGCT
CGTAAAGACATTCCAGTTTTACCCAAATGGGTTGGGGATCTTCCG
AATGGTAGAGTGTGTCCCTGAGATGGAATCAGCTTGAGTCTTCTG
CAATTGGTCACAACTATTCATGCTTCCTGTGATTTTCATCCAATA
CTTACCTTGCCTACGATATCCCCTTTATCTCTAATCAGTTTATTT
TCTTTCAAATAAAAAATAACTATGAGCAACATAAAAAAAAAAAAAA


FIG.18A

>BS106 TRANSLATION

MKFLAVLVLLGVSI FLVSAQNPTTAAPADTYPATGPADDEAPDAE
TTAAATTATTAAPT TATTAASTTARKDIPVLPKWVGDL PNGRVCP


FIG.18B






Anti-BU101.3 Polyclonal

FIG.20A




Anti-Mam.1 Polyclonal

FIG.20B



Anti-BU101.3 Polyclonal

FIG.20C



Anti-Mam.1 Polyclonal

FIG.20D

Correlations Between Marker Expression and Clinical and Molecular Parameters

	BU101	BS106	Mamaglobin	CK19	
T Stage	0.003 (NS)	-0.13 (NS)	-0.03 (NS)	-0.03 (NS)	N=95
Grade	-0.14 (NS)	0.12 (NS)	0.03 (NS)	0.06 (NS)	N=90
N Stage	0.05 (NS)	0.06 (NS)	0.04 (NS)	0.19 (NS)	N=85
Nodes +	-0.02 (NS)	0.01 (NS)	0.05 (NS)	0.23 (NS)	N=85
ER	-0.18 (NS)	-0.10 (NS)	-0.23 (p=0.02)	-0.18 (NS)	N=99
PR	-0.18 (NS)	-0.10 (NS)	-0.23 (p=0.02)	-0.18 (NS)	N=99
HER2	-0.12 (NS)	0.36 (p=0.003)	0.11 (NS)	0.02 (NS)	N=67
P53	-0.19 (NS)	-0.16 (NS)	-0.02 (NS)	-0.14 (NS)	N=77
BU101	-----	-0.05 (NS)	0.37 (p=0.0001)	-0.04 (NS)	N=101
BS106	-0.05 (NS)	-----	0.004 (NS)	0.07 (NS)	N=101
Mamm	0.37 (p=0.0001)	0.004 (NS)	-----	0.07 (NS)	N=101

Pearson product moment correlations were calculated between each pair of variables. The only significant relationships observed are bolded and have included p values. NS=not significant

FIG.21